Home›Companies›Biotech & Pharma›Tern Therapeutics

OptoVista Holdings, LLC

Develops gene therapies for people with rare diseases.

Updated Nov 16, 2026·Latest SEC filing Sep 25, 2026·Suggest an edit

About Tern Therapeutics

Tern Therapeutics is a private company based in Washington, District of Columbia, incorporated in 2023 in Delaware. It has reported $10,706,331 raised in two offerings on Form D since September 2024. Its chief executive is Alexander Bailey.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Sep 11, 2026Sep 25, 2026$3,727,518fully sold7$532KEquityRule 506(c)Form D ↗
Aug 21, 2024Sep 6, 2024$6,978,813of $13.9M target4$1.7MEquityRule 506(c)Form D ↗
Total, two offerings$10,706,331

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Tern Therapeutics's Form D filed Sep 25, 2026.

MR
Matthew Rosini
Chief Financial and Administration Officer
On every Form D that Tern Therapeutics has filed: 2 filings, from Sep 6, 2024 to Sep 25, 2026.
AB
Alexander Bailey
Chief Executive Officer and director
On every Form D that Tern Therapeutics has filed: 2 filings, from Sep 6, 2024 to Sep 25, 2026.
KP
Kerry Propper
Director
On every Form D that Tern Therapeutics has filed: 2 filings, from Sep 6, 2024 to Sep 25, 2026.
SO
Steven Oliveira
Director
On every Form D that Tern Therapeutics has filed: 2 filings, from Sep 6, 2024 to Sep 25, 2026.
CO
Christina Ohnsman
Chief Medical Officer
On every Form D that Tern Therapeutics has filed: 2 filings, from Sep 6, 2024 to Sep 25, 2026.

Sources

  1. SECOptoVista Holdings, LLC filing history
  2. CompanyTern Therapeutics contact
  3. CompanyTern Therapeutics about
  4. CompanyTern Therapeutics news